Trade Ideas

Traders Sentiment

Technical Summary



Novartis to cut thousands of jobs in global revamp - paper

ZURICH, April 12 (Reuters) - Swiss drugmaker Novartis NOVN.S will cut thousands of jobs worldwide as it combines its pharma and oncology businesses in a reorganisation announced last week, Swiss newspaper Tages-Anzeiger reported on Tuesday, citing unnamed company sources. More than 100 jobs could also disappear at Novartis's Swiss sites in Rotkreuz

UK Stocks-Factors to watch on Dec. 22

Dec 22 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher on Wednesday, with futures FFIc1 up 0.28%. * METRO BANK: The Bank of England's Prudential Regulation Authority has fined Metro Bank METRO.L 5.38 million pounds ($7.13 million) for failures in its regulatory reporting governance and controls, it said. * TAYLOR WIMPEY: UK's thir

Novartis CEO says Sandoz attracting interest - paper

ZURICH, Dec 10 (Reuters) - Novartis's NOVN.S potential sale of its Sandoz generic drug business is attracting interest from possible buyers, Chief Executive Vas Narasimhan said in an interview to be published on Friday. The Swiss pharmaceuticals company raised the prospect of divesting Sandoz in October after years of revamping the business, as pri

Novartis chairman says all options open for Sandoz unit - report

ZURICH, Nov 30 (Reuters) - Novartis NOVN.S is keeping all options open for the future of its generics division Sandoz, its chairman said in an interview with Swiss TV channel TeleZüri to be broadcast on Tuesday. Asked whether Novartis could merge Sandoz with either Israel's Teva TEVA.TA or U.S.-based Viatris VTRS.O or divest it, Joerg Reinhardt sa

Roche shareholders approve deal to buy Novartis's $20.7 billion stake

ZURICH, Nov 26 (Reuters) - Roche ROG.S shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's NOVN.S nearly one third voting stake, the Swiss drugmaker said. Roche held an extraordinary general meeting to settle matters related to its plan to disentangle the two pharma companies, both based in Basel, who had


Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.